<DOC>
	<DOCNO>NCT02302235</DOCNO>
	<brief_summary>The goal present study evaluate efficacy , safety tolerability 4:1 ketogenic diet administer adjunctively standard radiation temozolomide chemotherapy patient GBM prospective , randomized open label study .</brief_summary>
	<brief_title>Ketogenic Diet Treatment Adjunctive Radiation Chemotherapy Glioblastoma Multiforme : Pilot Study</brief_title>
	<detailed_description>Primary aim study 1 ) To evaluate efficacy ketogenic diet adjunctive treatment radiation treatment glioblastoma multiforme . 2 ) To evaluate safety ketogenic diet adjunctive treatment radiation treatment glioblastoma multiforme . Secondary aim evaluate tolerability ketogenic diet adjunctive treatment radiation treatment glioblastoma multiforme . Participants see one , 2 week , 4 week KG diet initiation , monthly month 6 diet initiation , every 2 month 2 year treatment initiation death , every 3 month 3 year treatment initiation death . KD treatment last 6 month exit criterion meet , whichever come first . Exit criterion primary outcome measure , first either ( ) MRI tumor progression ( b ) death . Secondary outcome measure include treatment compliance , hunger scale score , fast serum glucose BOH level occurrence adverse event . Patients document tumor progression receive standard care progressive GBM direct treat oncologist , independent study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>1 . Age 1865 2 . Ability willingness sign informed consent form 3 . Astrocytoma grade 4 ( glioblastoma multiforme , GBM , histologically confirm , WHO criteria ) 4 . Documented surgical resection/debulking 5 . Measurable contrastenhancing GBM MRI image ≤ two week screen prior surgery do ≤ 2 month 6 . Karnovsky Performance Score 70 1 . Acute intracranial intratumoral hemorrhage &gt; Grade 1 either MRI CT scan ≤2 week screen . ( Subjects resolve hemorrhage change , punctate hemorrhage , hemosiderin may enter study ) 2 . Prior treatment follow : ( ) smallmolecule kinase inhibitor ; ( b ) noncytotoxic hormonal agent ; ( c ) KD ≤6 month enrollment 3 . Planned continued use glucocorticoid 4 . Anticoagulation treatment ≥ 1 mg/day coumadin ≤ 7 day prior screen ( lowdose [ ≤ 1 mg/day ] coumadin , heparin , lowmolecularweight heparin permit ) 5 . Any systemic illness unstable medical condition might pose additional risk , include : cardiac , unstable metabolic endocrine disturbance , renal liver disease , past history renal calculus , hyperuricemia , hypercalcemia , mitochondrial disease , know disorder fatty acid metabolism , porphyria , carnitine deficiency pancreatitis 6 . History nonglioma malignancy : 1 . Surgically excised nonmelanoma skin cancer situ carcinoma cervix 2 . A malignancy diagnose ≥2 year ago subject evidence disease 2 year prior screen 7 . History uncontrolled hyperlipidemia 8 . Active drug alcohol dependence factor , opinion site investigator would interfere adherence study requirement 9 . History human immunodeficiency virus , hepatitis C 10 . Failure recover &lt; CTCAE grade 2 toxicity relate prior therapy 11 . Pregnancy breastfeed 12 . Use investigational drug within 1 month enrollment 13 . Inability unwillingness subject give write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Glioblastoma multigorme</keyword>
	<keyword>Ketogenic Diet</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>safety</keyword>
	<keyword>efficiency</keyword>
</DOC>